Ribosomal protein S7 as a novel modulator of p53–MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function (original) (raw)

• Attardi LD, Jacks T . (1999). The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 55: 48–63.
  Article CAS PubMed Google Scholar
• Bhat KP, Itahana K, Jin A, Zhang Y . (2004). Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J 23: 2402–2412.
  Article CAS PubMed PubMed Central Google Scholar
• Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591–602.
  Article CAS PubMed Google Scholar
• Budde A, Grummt I . (1999). p53 represses ribosomal gene transcription. Oncogene 18: 1119–1124.
  Article CAS PubMed Google Scholar
• Dai M, Lu H . (2004). Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 279: 44475–44482.
  Article CAS PubMed Google Scholar
• Dai M, Shi D, Jin Y, Sun X, Zhang Y, Grossman SR et al. (2006). Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem 281: 24304–24313.
  Article CAS PubMed PubMed Central Google Scholar
• Dai M, Zeng S, Jin Y, Sun X, David L, Lu H . (2004). Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 24: 7654–7668.
  Article CAS PubMed PubMed Central Google Scholar
• Du YC, Stillman B . (2002). Yph1p, an ORC-interacting protein: potential links between cell proliferation control, DNA replication, and ribosome biogenesis. Cell 109: 835–848.
  Article CAS PubMed Google Scholar
• Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G et al. (2006). Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 103: 3232–3237.
  Article CAS PubMed Google Scholar
• Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H et al. (2003). Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300: 342–344.
  Article CAS PubMed Google Scholar
• Haupt Y, Maya R, Kazaz A, Oren M . (1997). Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
  Article CAS PubMed Google Scholar
• Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y et al. (2005). The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 8: 75–87.
  Article CAS PubMed Google Scholar
• Jin Y, Lee H, Zeng SX, Dai MS, Lu H . (2003). MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J 22: 6365–6377.
  Article CAS PubMed PubMed Central Google Scholar
• Lane DP . (1992). p53, guardian of the genome. Nature 358: 15–16.
  Article CAS PubMed Google Scholar
• Lane DP, Hall PA . (1997). MDM2-arbiter of p53's destruction. Trends Biochem Sci 22: 372–374.
  Article CAS PubMed Google Scholar
• Levine AJ . (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
  Article CAS PubMed Google Scholar
• Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J et al. (2002). Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648–653.
  Article CAS PubMed Google Scholar
• Li M, Zhang Z, Hill DL, Chen X, Wang H, Zhang R . (2005). Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 65: 8200–8208.
  Article CAS PubMed Google Scholar
• Liu G, Chen X . (2006). DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation. Mol Cell Biol 26: 1398–1413.
  Article CAS PubMed PubMed Central Google Scholar
• Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH . (2003). Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3: 577–587.
  Article CAS PubMed Google Scholar
• Pestov DG, Strezoska Z, Lau LF . (2001). Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition. Mol Cell Biol 21: 4246–4255.
  Article CAS PubMed PubMed Central Google Scholar
• Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713–723.
  Article CAS PubMed Google Scholar
• Poyurovsky MV, Prives C . (2006). Unleashing the power of p53: lessons from mice and men. Genes Dev 20: 125–131.
  Article CAS PubMed Google Scholar
• Sui G, Affar el B, Shi Y, Brignone C, Wall NR, Yin P et al. (2004). Yin Yang 1 is a negative regulator of p53. Cell 117: 859–872.
  Article CAS PubMed Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844–848.
  Article CAS PubMed Google Scholar
• Vogelstein B, Lane D, Levine AJ . (2000). Surfing the p53 network. Nature 408: 307–310.
  Article CAS PubMed Google Scholar
• Wang H, Yu D, Agrawal S, Zhang R . (2003). Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 54: 194–205.
  Article CAS PubMed Google Scholar
• Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR et al. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694–698.
  Article CAS PubMed Google Scholar
• Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G . (2006). Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci USA 103: 3226–3231.
  Article CAS PubMed Google Scholar
• Zhang R, Wang H, Agrawal S . (2005a). Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr Cancer Drug Targets 5: 43–49.
  Article PubMed Google Scholar
• Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA et al. (2003a). Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 23: 8902–8912.
  Article CAS PubMed PubMed Central Google Scholar
• Zhang Y, Xiong Y, Yarbrough WG . (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734.
  Article CAS PubMed Google Scholar
• Zhang Z, Li M, Wang H, Agrawal S, Zhang R . (2003b). Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 100: 11636–11641.
  Article CAS PubMed Google Scholar
• Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R . (2004). MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 279: 16000–16006.
  Article CAS PubMed Google Scholar
• Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R . (2005b). Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 24: 7238–7247.
  Article CAS PubMed Google Scholar
• Zhang Z, Zhang R . (2005). p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 5: 9–20.
  Article PubMed Google Scholar
• Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC . (2001). HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973–982.
  Article CAS PubMed Google Scholar